Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- How Unpopular Is Big Business?
- When Gallup asked Americans if the earth revolves around the sun, 79% said yes. Shocked that 21% disagreed? That lack of general knowledge may be alarming, but for folks in business it might be more shocking to know that more Americans believe big business is untrustworthy than have a...
- Blog posts 2008-01-16
- A Cure for Clinical Trials
- US pharma companies often miss their deadlines when testing new drugs. The use of marketing techniques to manage the recruitment of patients for clinical trials could speed things up considerably. Testing new drugs is a costly and frustrating headache for pharmaceuticals companies—and the pain is about to get worse. Clinical...
- White papers 2002-01-01
- Pharmaceutical Clinical Development: Realizing the Full Rewards of Electronic Data Capture (EDC)
- Clinical trials play a key role in the pharmaceuticals industry. With a large number of drugs coming off patent, pharmaceutical companies are under pressure to develop and test new drugs as quickly and efficiently as possible. This requires an increase in clinical trials and a reduction in the cycle time...
- White papers 2002-06-01
- West Pharmaceutical Services
- West Pharmaceutical Services, Inc. (NYSE:WST) is a global drug delivery technology company that applies proprietary materials science, formulation research and manufacturing innovation to advance the quality, therapeutic value, development speed and rapid market availability of pharmaceuticals, biologics, vaccines and consumer healthcare products. When an explosion ripped through its Kinston, N.C.,...
- Case studies
- Pharmaceuticals/Health Care: Safety and Security in the Spotlight
- This article discusses about the safety and security in healthcare and pharmaceutical sector. The U.S. business community?and society in general?have become markedly more security conscious following the havoc of 9/11, and this new awareness has spotlighted the vulnerability of food and drug supply chains. Regulatory watchdogs of the already highly...
- White papers 2004-06-01
- Access to Medicines and Pharmaceutical Patents
- All countries agreed, in principle that, in circumstances of national health emergencies, developed countries should be allowed to grant compulsory licenses to manufacture generic pharmaceuticals for export to countries, which lack pharmaceutical manufacturing capacity. However, there is no agreement on the appropriate definition of health emergency and without this the...
- White papers
- The Medicare Prescription Drug, Improvement, and Modernization Act of 2003: How Will Pharmaceutical Companies Be Affected and How Should They Respond
- The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 will have significant effects on the 43% of pharmaceutical industry revenues that are derived from Medicare beneficiaries. The Act's wide-ranging effects include the following of particular interest to pharmaceutical companies as is mentioned in the report. The report estimated that...
- White papers 2004-01-01
- Caught in the Cross Chairs
- The pharmaceutical industry stands in the crosshairs of federal and state law enforcement agencies. It is not being targeted by FDA for regulatory violations, as one would expect, but by many other government agencies. Some of the issues in question are the way pharma companies calculate and report product prices...
- White papers 2002-04-15
- Pharma 2005 Marketing to the Individual
- The world in which all live is changing, and the PricewaterhouseCoopers Global Pharmaceutical Practice has taken on the challenge of exploring the future and its implications for today's pharmaceutical companies. From the forces converging on the individual to the acceleration of change due to the e-environment, we have explored multiple...
- White papers 2001-05-15
- Process Validation: Moist Heat Sterilization for Pharmaceuticals
- This document is intended to provide manufacturers of pharmaceutical dosage forms with guidance to establish the scientific effectiveness of moist heat sterilization processes, as required in Sections C.02.004, C.02.005, C.02.007, C.02.011 and C.02.029 of the Food and Drug Regulations. This guideline is applicable to moist heat sterilization processes only. While...
- White papers 2001-05-01
- Improving Access to Drugs for Medicare Beneficiaries: Can State Laws Help?
- Although elderly Medicare beneficiaries account for more than a third of the nation's pharmaceutical expenditures, the Medicare program currently offers no prescription drug coverage. While the federal government considers various ways to make prescription drugs more affordable for this population, a number of states, including California, have passed laws creating...
- White papers
- Guidance for R&D Managers in NHS Trusts and Clinical Research Departments in the Pharmaceutical Industry
- This guidance has been developed firstly to facilitate, where appropriate, the introduction and use of the model Clinical Trial Agreement (model CTA, attached). The model is specifically for use in connection with contract clinical trials sponsored by pharmaceutical companies and carried out by NHS Trusts in England. Secondly, it is...
- White papers 2003-01-27
- Big Pharma Can Still Find Big Value in E-Health
- Almost all pharmaceutical companies have moved online, but the big gains they anticipated have largely failed to materialize. Now that the early euphoria is gone, many executives believe that Internet-based technologies can generate only incremental value. But although e-health is not a panacea, neither is it a pill without a...
- White papers 2001-03-21
- Highlights From the Pharmaceutical Industry Profile
- This report reviews the pharmaceutical industry during the year 2003. Patient care has changed significantly over the past 25 years. Medicines now exist to treat conditions that had no treatment a quarter century ago. At that time, lengthy hospital stays, surgery, and time away from family and jobs were common...
- White papers 2003-10-07
- High-Cost Users of Pharmaceuticals: Who Are They?
- For a long time that health care resources and costs are concentrated on a relatively small proportion of the population. These high-level consumers of health care have gained the negative reputation of being "high users" and provide an obvious target for cost containment. With the rising costs of pharmaceuticals over...
- White papers 2005-03-01
- The Coming Paradigm Shift in Pharmaceuticals
- This article explores the coming paradigm shift and the opportunities it presents for the future of pharmaceuticals. This article discusses how Pharmacogenomics holds the promise of more effective and better-tolerated therapies, which, in turn, mean more efficient use of healthcare resources. The article further goes on to discuss several hurdles...
- White papers 2002-09-30
- Demonstrating the Value of Pharmaceuticals Across the Healthcare Continuum
- This document debates and explores medical innovation and the role of pharmaceuticals in the delivery of high-quality healthcare. This article examines and discusses the trends in healthcare consumerism, FDA movements to ensure safety, improvements in disease-state outcomes, increases in quality of life, and the economics associated with all these complex...
- White papers 2004-02-01
- Dilemmas in Regulation of the Market for Pharmaceuticals
- This article focuses on the lessons learned from international experience of efforts to control spending and to improve efficiency and access in pharmaceutical markets? Policymakers tend to reinvent many policies to control the behavior of patients, doctors, and industry, despite a lack of evidence of those policies' cost-effectiveness. There is...
- White papers 2003-04-21
- A New Rx for Corporate Disclosure: Realizing Value in the Pharmaceutical and Healthcare Products Industries
- This paper focuses on the pharmaceutical and healthcare products industries. It identifies a significant number of opportunities for companies to improve their communications with investors and analysts and, thereby, disclose information to the capital markets that reveals their underlying value. It proposes a new reporting framework, which includes a set...
- White papers 2001-10-25
- SAP for Life Sciences in the Pharmaceutical Industry
- The life sciences industry is dynamic - always innovating, always in flux. What worked yesterday might not work today. That's why pharmaceutical, biotechnology, and medical device companies are constantly seeking better ways to manage complexity, comply with regulations, cut costs, and boost productivity. In pursuit of these objectives, life sciences...
- White papers 2003-12-02
- << Previous
- page 1 of 3
- Next >>
Content Types
Refining Tags
- Vertical Industries (28 results)
- Enterprise Software (27 results)
- Software (27 results)
- Health Care (26 results)
- Benefits (26 results)
- Human Resources (26 results)
- Jim Edwards (6 results)
- Manufacturing (5 results)
- Finance (5 results)
- John Maas (5 results)
- Business Operations (5 results)
- Seeking Alpha (5 results)
- Public Health (5 results)
- Medicare (5 results)
- Pfizer Inc. (4 results)
- Microsoft Access (4 results)
- PricewaterhouseCoopers LLP (3 results)
- Clinical Trial (3 results)
- Biotechnology (3 results)
- Drug Company (3 results)
- Management (3 results)
- Research & Development (3 results)
- Project HOPE (3 results)
Presented by American Express